CZ20011142A3 - Léková forma pro perorální podání - Google Patents

Léková forma pro perorální podání Download PDF

Info

Publication number
CZ20011142A3
CZ20011142A3 CZ20011142A CZ20011142A CZ20011142A3 CZ 20011142 A3 CZ20011142 A3 CZ 20011142A3 CZ 20011142 A CZ20011142 A CZ 20011142A CZ 20011142 A CZ20011142 A CZ 20011142A CZ 20011142 A3 CZ20011142 A3 CZ 20011142A3
Authority
CZ
Czechia
Prior art keywords
oral dosage
dosage form
separate oral
form according
separate
Prior art date
Application number
CZ20011142A
Other languages
Czech (cs)
English (en)
Inventor
Samuel Bruce Balik
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CZ20011142A3 publication Critical patent/CZ20011142A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CZ20011142A 1998-09-28 1999-09-24 Léková forma pro perorální podání CZ20011142A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28

Publications (1)

Publication Number Publication Date
CZ20011142A3 true CZ20011142A3 (cs) 2001-09-12

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20011142A CZ20011142A3 (cs) 1998-09-28 1999-09-24 Léková forma pro perorální podání

Country Status (17)

Country Link
EP (1) EP1117407A1 (fr)
JP (1) JP2002525328A (fr)
KR (1) KR20010075385A (fr)
CN (1) CN1328459A (fr)
AR (1) AR022673A1 (fr)
AU (1) AU6087399A (fr)
BR (1) BR9914096A (fr)
CA (1) CA2345638A1 (fr)
CZ (1) CZ20011142A3 (fr)
HU (1) HUP0103459A2 (fr)
IL (1) IL142054A0 (fr)
MA (1) MA26693A1 (fr)
NO (1) NO20011555D0 (fr)
PE (1) PE20001087A1 (fr)
PL (1) PL346877A1 (fr)
TR (1) TR200100863T2 (fr)
WO (1) WO2000018406A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220673A2 (fr) * 1999-10-13 2002-07-10 Glaxo Group Limited Methode destinee au traitement de l'obesite
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
PL346877A1 (en) 2002-03-11
CA2345638A1 (fr) 2000-04-06
TR200100863T2 (tr) 2001-07-23
AR022673A1 (es) 2002-09-04
BR9914096A (pt) 2001-07-31
JP2002525328A (ja) 2002-08-13
WO2000018406A1 (fr) 2000-04-06
HUP0103459A2 (hu) 2002-01-28
NO20011555L (no) 2001-03-27
PE20001087A1 (es) 2000-10-20
EP1117407A1 (fr) 2001-07-25
AU6087399A (en) 2000-04-17
IL142054A0 (en) 2002-03-10
MA26693A1 (fr) 2004-12-20
KR20010075385A (ko) 2001-08-09
NO20011555D0 (no) 2001-03-27
CN1328459A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
RU2405540C1 (ru) Таблетка с высоким содержанием лекарственного препарата
JP5886632B2 (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
EP1670440B1 (fr) Formulations hrt
EA003217B1 (ru) Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов
JP2008503475A (ja) メマンチンの放出が改変された製剤
KR20100121509A (ko) 구강 내 붕괴정
CN101925349A (zh) 替马西泮的口腔崩解片组合物
WO2020239986A1 (fr) Composition de comprimé pharmaceutique comprenant de l'edoxaban
WO2006115770A2 (fr) Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale
HU228179B1 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
US20170014340A1 (en) Orally Disintegrating Tablet of Nabilone Comprising Mannitol-Based Granules
WO2020175897A1 (fr) Formulation à libération contrôlée contenant du mirabegron ou un sel pharmaceutiquement acceptable de ce dernier
JP3884056B1 (ja) 口腔内速崩錠の製造方法
WO2002058666A2 (fr) Procede pour la preparation d'une composition de valproate de sodium non hygroscopique
JP5318400B2 (ja) レボフロキサシン含有錠剤
RU2613192C1 (ru) Таблетки клозапина с пролонгированным высвобождением
EP3501506B1 (fr) Composition de comprimé pharmaceutique comprenant du brexpiprazole
CZ20011142A3 (cs) Léková forma pro perorální podání
JP2003520252A (ja) テルビナフィン含有医薬組成物
JPWO2003075919A1 (ja) 塩酸ピルジカイニド含有錠剤（乾式）
JP2006510665A (ja) 新規な経口即時放出型投与剤形
JP2002020282A (ja) プラバスタチン含有組成物
MXPA01003130A (en) Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid
JP7195660B1 (ja) 口腔内崩壊錠
WO2005016315A1 (fr) Compositions pharmaceutiques de nateglinide